UNSPSC 51362001: Cyprazepam

This classification denotes a benzodiazepine with the molecular formula C19H18ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 933N61G4SL, chemically known as 7-chloro-2-((cyclopropylmethyl)amino)-5-phenyl-3h-1,4-benzodiazepine 4-oxide but generally known as cyprazepam, which bears US NIH Compound Identifier 27452. European Medicines Agency schedules Cyprazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06872MIG.

UNSPSC 51362001 Cyprazepam is a Commodity code that does not reflect the pharmaceutical procurement activity currently appearing under this classification in state and local solicitations. The three recent opportunities posted under this code involve naloxone and drug deactivation systems, a direct-to-manufacturer prescription program, and generic multi-source pharmaceuticals and OTC products — none of which are cyprazepam, a benzodiazepine with limited contemporary procurement visibility in state and local markets. The mismatch between the code's nominal scope and actual solicitation content suggests either misclassification in the underlying procurement system or that this Commodity code is used as a catch-all placeholder for broader pharmaceutical purchasing rather than for cyprazepam specifically.

The issuing bodies span state health and human services agencies, county health departments, and cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023, per the source timeline) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon. The geographic spread reflects activity in Florida, Texas, Minnesota, and Oregon, with cooperative purchasing vehicles playing a significant role in multi-jurisdictional pharmaceutical procurement.